ID: ALA5205857

Max Phase: Preclinical

Molecular Formula: C20H25N7O3

Molecular Weight: 411.47

Associated Items:

Representations

Canonical SMILES:  N#Cc1cc(N)ncc1-c1cc(N2CCOC(CCO)C2)nc(N2CCOCC2)n1

Standard InChI:  InChI=1S/C20H25N7O3/c21-11-14-9-18(22)23-12-16(14)17-10-19(27-4-8-30-15(13-27)1-5-28)25-20(24-17)26-2-6-29-7-3-26/h9-10,12,15,28H,1-8,13H2,(H2,22,23)

Standard InChI Key:  BAXGOTAGIFYOFF-UHFFFAOYSA-N

Associated Targets(non-human)

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 37 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 66 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 411.47Molecular Weight (Monoisotopic): 411.2019AlogP: 0.42#Rotatable Bonds: 5
Polar Surface Area: 133.65Molecular Species: NEUTRALHBA: 10HBD: 2
#RO5 Violations: 0HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 4.81CX LogP: 0.97CX LogD: 0.97
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.71Np Likeness Score: -1.09

References

1. Fairhurst RA, Furet P, Imbach-Weese P, Stauffer F, Rueeger H, McCarthy C, Ripoche S, Oswald S, Arnaud B, Jary A, Maira M, Schnell C, Guthy DA, Wartmann M, Kiffe M, Desrayaud S, Blasco F, Widmer T, Seiler F, Gutmann S, Knapp M, Caravatti G..  (2022)  Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,  65  (12.0): [PMID:35500094] [10.1021/acs.jmedchem.2c00267]

Source